BPC 157: Miracle Healing Peptide or Hidden Danger? On August 15 2025, the U.S. Food & Drug Administration (FDA) issued a Warning Letter to Platinum Biologics LLC for marketing umbilicalcordderived products including exosome products (NanoEx & Nano Xsomes) without approval. BPC 157 Erectile Dysfunction Study: What the Evidence Actually Shows The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Compliance for Peptide Therapy and BPC 157 Holt Law FDA warning letters target marketers of unapproved weight loss drugs RAPS